Page last updated: 2024-08-26

nicotine and Idiopathic Parkinson Disease

nicotine has been researched along with Idiopathic Parkinson Disease in 123 studies

Research

Studies (123)

Timeframe	Studies, this research(%)	All Research%
pre-1990	13 (10.57)	18.7374
1990's	25 (20.33)	18.2507
2000's	40 (32.52)	29.6817
2010's	34 (27.64)	24.3611
2020's	11 (8.94)	2.80

Authors

Authors	Studies
Elgayar, SAM; Gomaa, AMS; Hussein, OA; Ismaiel, AM; Mubarak, HA	1
Bagchi, A; Biswas, S	1
Clemens, SG; Feany, MB; Olsen, AL	1
Dulcis, D; Keisler, M; Lai, JI; Manfredsson, FP; Porcu, A; Powell, SB; Romoli, B	1
Becerra, GP; González, J; Loaiza, AE; Mejía, SM; Ramírez, D; Rojas-Rodríguez, F; Tobar-Tosse, F	1
Ascherio, A; Gao, X; Li, Y; Ma, C; Molsberry, S; Schwarzschild, M	1
Lao-Kaim, NP; Piccini, P; Roussakis, AA; Zeng, Z	1
Torrey, EF	1
Campusano, JM; Carvajal-Oliveros, A; Domínguez-Baleón, C; Narváez-Padilla, V; Reynaud, E; Zárate, RV	1
Aschner, M; Getachew, B; Tizabi, Y	1
Maruyama, H; Neshige, R; Neshige, S; Ohshita, T	1
Audureau, E; Cormier-Dequaire, F; Damier, P; Defer, G; Evangelista, E; Fénelon, G; Gurruchaga, JM; Itti, E; Kerschen, P; Paul, M; Quéré-Carne, M; Remy, P; Straczek, C; Thiriez, C; Van Der Gucht, A; Villafane, G	1
Domingos, J; Hägglund, M; Riggare, S; Stamford, JA; Sturr, J; Svenningsson, P; Unruh, KT	1
DiFrancisco-Donoghue, J; Jung, MK; Leder, A	1
Asadi-Shekaari, M; Eftekhar-Vaghefi, SH; Elyasi, L; Esmaeili-Mahani, S	1
Abin-Carriquiry, JA; Costa, G; Dajas, F; Ferreira, M; Mouhape, C; Prunell, G	1
Bender, CA; Francisco, AB; Glorioso, C; Libert, S; Lugay, FJ; Nicholatos, JW; Salazar, JE; Yeh, T	1
Aschner, M; Csoka, AB; Getachew, B; Tizabi, Y	1
Anderson, G; Maes, M	1
Buhlman, LM; Call, GB; Chambers, RP; Meyer, D; Pearman, K; Smith, J; Techau, JA	1
Bencherif, M; Carroll, FI; Letchworth, S; Mallela, A; Quik, M; Sohn, D; Zhang, D	1
Kaakkola, S; Tuominen, R	1
Budzianowski, J	1
Henderson, BJ; Lester, HA; Richards, CI; Srinivasan, R	1
Bar-Shira, A; Gan-Or, Z; Gana-Weisz, M; Giladi, E; Giladi, N; Orr-Urtreger, A	1
Dmitriev, O; Kakish, J; Lee, JS; Nokhrin, S; Tavassoly, O	1
Felson, DT; Zhang, Y	1
Bordia, T; Perez, XA; Quik, M; Zhang, D	1
Jakova, E; Lee, JS	1
Haining, RL; Hernandez, A; Jones, TM	1
Kardani, J; Roy, I; Sethi, R	1
Bernstein, AI; Cai, H; Caudle, WM; Dunn, AR; Hoffman, CA; Li, Y; Lohr, KM; Miller, GW; Ozawa, M; Sastry, N; Sgobio, C; Stout, KA; Wang, M	1
Bordia, T; Campos, C; Huang, L; Quik, M	1
O'Leary, K; Quik, M; Tanner, CM	1
Choonara, YE; du Toit, LC; Khan, RA; Pillay, V; Singh, N	1
Fink, AL; Hong, DP; Uversky, VN	1
Zhao, B	1
Banghart, MR; Dougherty, DA; Goate, AM; Lester, HA; Miwa, J; Pantoja, R; Son, CD; Srinivasan, R; Wang, JC; Xiao, C	1
Da Cunha, C; Ferro, MM; Gregório, ML; Silveira, JL; Vital, MA; Wietzikoski, EC	1
Bordia, T; Campos, C; Huang, LZ; Parameswaran, N; Perez, XA; Quik, M	1
Brugières, P; Capacchione, D; Cesaro, P; Itti, E; Itti, L; Maison, P; Malek, Z; Meignan, M; Villafane, G	1
Jin, GZ; Wu, J; Yang, KC	1
Bencherif, M; Breining, SR; Grady, SR; Lester, HA; Marks, MJ; Wageman, CR; Whiteaker, P; Yohannes, D	1
Nath, C; Patel, DK; Singh, C; Singh, K; Singh, MP; Singh, RK; Singh, S; Singh, VK	1
Parmar, D; Sharma, A; Singh, K; Singh, MP; Singh, S; Singhal, NK	1
Andrews, L; Gelb, M; Hanak, T; Krause, J; Lee, D; Pallanck, L; Trinh, K	1
Feng, YH; Li, Y; Peng, Y; Sun, YP; Yu, DQ; Zhang, DM; Zhang, WQ; Zhao, J	1
Chenery, HJ; Copland, DA; Holmes, AD; Silburn, PA	2
Cardinale, A; Cesario, A; Nastrucci, C; Russo, P	1
Cesaro, P; Fenelon, G; Grapin, F; Remy, P; Thiriez, C; Villafane, G	1
Kawamata, J; Shimohama, S; Suzuki, S	1
Caviedes, P; Cuevas, C; Huenchuguala, S; Muñoz, P; Paris, I; Segura-Aguilar, J; Tizabi, Y; Villa, M	1
Day, BL; Lees, AJ; Ling, H; Petrovic, I	1
Bordia, T; Perez, XA; Quik, M	1
Bharath, MM; Harish, G; Mythri, RB	1
Factor, SA; Feany, MB; Frodey, K; Ganguly, P; Hamza, TH; Hanes, SD; Hill-Burns, EM; Kay, DM; McLear, JA; Montimurro, J; Payami, H; Sheehan, P; Singh, N; Wolfgang, WJ; Yearout, D; Zabetian, CP	1
Bargas, J; Boronat-García, A; Drucker-Colín, R; García-Montes, JR; Guerra-Crespo, M; López-Colomé, AM	1
Kulak, JM; Quik, M	1
Gale, C; Martyn, C	1
Chai, A; Chandran, VR; Chung, H; Fook-Chong, SM; Lum, SY; Pavanni, R; Shen, H; Tan, C; Tan, EK; Teoh, ML; Wong, MC; Yih, Y; Zhao, Y	1
Bédard, MA; Beuter, A; Blanchet, P; Chouinard, S; Lemay, S; Masson, H; Soland, V	1
BOVET, D; DUREL, P; LONGO, V	1
Nagata, K	1
Quik, M	1
Alves, G; Kurz, M; Larsen, JP; Lie, SA	1
Langmeier, M; Riljak, V	1
Bordia, T; Fan, H; Langston, JW; McIntosh, JM; Parameswaran, N; Quik, M	1
Miksys, S; Tyndale, RF	1
Choonara, YE; Pillay, V; Singh, N	1
O'Neill, M; Perez, XA; Quik, M	1
Ahn, YW; Choi, YJ; Chung, ES; Jin, BK; Lee, DY; Lee, G; Lee, PH; Park, HJ	1
Bordia, T; O'Leary, K; Quik, M	1
Azimi, S; Baloul, S; Bourdet, C; Cesaro, P; Le Houezec, J; Macquin-Mavier, I; Maison, P; Rialland, A; Villafane, G	1
Picciotto, MR; Zoli, M	1
Checkoway, H; Factor, SA; Griffith, A; Higgins, DS; Kay, DM; Leis, B; Martinez, ED; Montimurro, JS; Nutt, JG; Payami, H; Powers, KM; Roberts, JW; Samii, A; Zabetian, CP	1
Baumann, RJ; Haack, DG; Jameson, HD; McKean, HE; Turbek, JA	1
Heberlein, I; Vieregge, P	1
James, JR; Nordberg, A	1
Baron, JA; Clemens, P; Coffey, D; Reeves, A	1
Levin, ED; Rose, JE; Westman, EC	1
Fagerström, KO; Giordani, B; Pomerleau, O; Stelson, F	1
Ishikawa, A; Miyatake, T	1
Balfour, DJ; Fagerström, KO	1
Erdmann, R	1
Levin, ED; Newhouse, PA; Potter, A	1
Nishimura, H; Okuda, B; Sugita, M; Tachibana, H	1
Lindstrom, J	1
Cui, WY; Gao, ZG; Liu, CG; Zhang, HT	1
Armogida, M; Corsini, GU; Fornai, F; Maggio, R; Molteni, R; Racagni, G; Riva, M; Vaglini, F	1
Mathé, JM; Nomikos, GG; Schilström, B; Svensson, TH	1
Gorell, JM; Johnson, CC; Peterson, EL; Rybicki, BA	1
Arendash, GW; Bjugstad, KB; Bridge, MH; Grossman, S; Huber, M; Linert, W	1
Ebersbach, G; Müller, J; Poewe, W; Stöck, M; Wenning, G; Wissel, J	1
Ballard, CG; Cookson, N; Court, JA; Lloyd, S; McKeith, IG; Perry, EK; Perry, RH; Piggott, MA	1
Arun, P; Deepadevi, KV; Kurup, PA; Manojkumar, V; Ravikumar, A	1
Court, JA; Gotti, C; Lindstrom, J; Martin-Ruiz, CM; Mendelow, AD; Perry, EK; Perry, RH; Piggott, M; Siddique, MS	1
Drucker-Colín, R; Mihailescu, S	1
Danysz, W	1
Hagenah, JM; Jacobs, H; Sieberer, M; Vieregge, A; Vieregge, P	1
Petrovitch, H; Ross, GW	1
Jeyarasasingam, G; Quik, M; Tompkins, L	1
Allam, MF	1
Paulson, GW	1
Araujo, DM; Aubert, I; Cécyre, D; Gauthier, S; Quirion, R; Robitaille, Y	1
Benowitz, NL; Le Houezec, J	1
Moochhala, SM; Shahi, GS	1
Hofman, A; van Duijn, CM	1
Lönnberg, P; Marjamäki, P; Myllykylä, T; Rinne, JO	1
Fiske, LA; Fung, YK; Lau, YS	1
Blessed, G; Candy, JM; Dick, DJ; Edwardson, JA; Fairbairn, A; Perry, EK; Perry, RH; Smith, CJ	1
Kellar, KJ; Marcus, KA; Martino, AM; Price, DL; Singer, HS; Whitehouse, PJ; Zweig, RM	1
Koller, WC; Royse, V; Zdonczyk, D	1
Perry, TL; Yong, VW	1
Hashim, A; Lajtha, A; Sershen, H	1
Baron, JA	1
Nordberg, A; Nyberg, P; Windblad, B	1
Kessler, II	1
Diamond, EL; Kessler, II	1
Bhargava, LP; Dandiya, PC	1
Marshall, J; Schnieden, H	1

Reviews

40 review(s) available for nicotine and Idiopathic Parkinson Disease

Article	Year
Astrocytes in Parkinson's disease: from preclinical assays to in vivo imaging and therapeutic probes. Neurobiology of aging, 2020, Volume: 95 Topics: Aging; alpha-Synuclein; Antioxidants; Astrocytes; Cholinergic Agonists; Disease Progression; Gliosis; Glutathione; Humans; Nerve Growth Factors; Nicotine; Parkinson Disease; Purinergic Antagonists; Risk Factors	2020
Novel Pharmacotherapies in Parkinson's Disease. Neurotoxicity research, 2021, Volume: 39, Issue:4 Topics: Animals; Antiparkinson Agents; Brain; Butyrates; Dopamine Agents; Dopaminergic Neurons; Drug Therapy, Combination; Humans; Levodopa; Nicotine; Parkinson Disease	2021
TRYCAT pathways link peripheral inflammation, nicotine, somatization and depression in the etiology and course of Parkinson's disease. CNS & neurological disorders drug targets, 2014, Volume: 13, Issue:1 Topics: Animals; Depression; Humans; Indoleamine-Pyrrole 2,3,-Dioxygenase; Inflammation; Nicotine; Parkinson Disease; Signal Transduction; Somatoform Disorders; Tryptophan	2014
[Nicotine and neurologic diseases--even a noxious substance may possess beneficial properties]. Duodecim; laaketieteellinen aikakauskirja, 2013, Volume: 129, Issue:16 Topics: Alzheimer Disease; Ataxia; Benzazepines; Cognitive Dysfunction; Epilepsy, Frontal Lobe; Humans; Mutation; Nicotine; Nicotinic Agonists; Parkinson Disease; Quinoxalines; Receptors, Nicotinic; Tobacco Use Cessation Devices; Varenicline	2013
[Tobacco--once a medicinal plant. Does it contain substances with medicinal properties?]. Przeglad lekarski, 2013, Volume: 70, Issue:10 Topics: Animals; Brain; Comorbidity; Humans; Monoamine Oxidase; Naphthoquinones; Neuroprotective Agents; Nicotiana; Nicotine; Nitric Oxide Synthase Type I; Parkinson Disease; Phytotherapy; Plants, Medicinal; Receptors, Nicotinic; Smoking	2013
Pharmacological chaperoning of nAChRs: a therapeutic target for Parkinson's disease. Pharmacological research, 2014, Volume: 83 Topics: Animals; Drug Discovery; Humans; Molecular Targeted Therapy; Neurons; Neuroprotective Agents; Nicotine; Parkinson Disease; Receptors, Nicotinic; Tobacco Use Disorder; Up-Regulation	2014
Smoking and osteoarthritis: a review of the evidence and its implications. Osteoarthritis and cartilage, 2015, Volume: 23, Issue:3 Topics: Body Mass Index; Colitis, Ulcerative; Confounding Factors, Epidemiologic; Humans; Musculoskeletal Pain; Nicotine; Osteoarthritis; Parkinson Disease; Protective Factors; Risk Factors; Smoking	2015
Nicotine and Nicotinic Receptor Drugs: Potential for Parkinson's Disease and Drug-Induced Movement Disorders. International review of neurobiology, 2015, Volume: 124 Topics: Antiparkinson Agents; Humans; Movement Disorders; Nicotine; Parkinson Disease	2015
Nicotine and Parkinson's disease: implications for therapy. Movement disorders : official journal of the Movement Disorder Society, 2008, Sep-15, Volume: 23, Issue:12 Topics: Animals; Antiparkinson Agents; Humans; Nicotine; Parkinson Disease	2008
Natural antioxidants protect neurons in Alzheimer's disease and Parkinson's disease. Neurochemical research, 2009, Volume: 34, Issue:4 Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Antioxidants; Flavonoids; Neurons; Nicotine; Oxidative Stress; Parkinson Disease; Phenols; Plaque, Amyloid; Polyphenols; Tea	2009
Nicotine is a selective pharmacological chaperone of acetylcholine receptor number and stoichiometry. Implications for drug discovery. The AAPS journal, 2009, Volume: 11, Issue:1 Topics: Acetylcholine; Animals; Drug Discovery; Endoplasmic Reticulum; Epilepsy, Frontal Lobe; Hippocampus; Mice; Models, Biological; Muscle Proteins; Mutation, Missense; Nerve Tissue Proteins; Neurotransmitter Agents; Nicotine; Parkinson Disease; Receptors, Nicotinic; Smoking; Tobacco Use Disorder; Up-Regulation; Ventral Tegmental Area	2009
Multiple roles for nicotine in Parkinson's disease. Biochemical pharmacology, 2009, Oct-01, Volume: 78, Issue:7 Topics: Animals; Antiparkinson Agents; Corpus Striatum; Humans; Levodopa; Motor Skills; Neuroprotective Agents; Nicotine; Nicotinic Agonists; Parkinson Disease; Receptors, Nicotinic; Smoking; Substantia Nigra	2009
Mysterious alpha6-containing nAChRs: function, pharmacology, and pathophysiology. Acta pharmacologica Sinica, 2009, Volume: 30, Issue:6 Topics: Animals; Dopamine; Drug Delivery Systems; Humans; Nicotine; Nicotinic Agonists; Nicotinic Antagonists; Parkinson Disease; Protein Subunits; Receptors, Nicotinic; Reward; Tobacco Use Disorder; Ventral Tegmental Area	2009
Nicotine: specific role in angiogenesis, proliferation and apoptosis. Critical reviews in toxicology, 2012, Volume: 42, Issue:1 Topics: Alzheimer Disease; Animals; Apoptosis; Cell Proliferation; Humans; Neovascularization, Pathologic; Neuroprotective Agents; Nicotine; Parkinson Disease; Protein Binding; Receptors, Nicotinic	2012
Can nicotine be used medicinally in Parkinson's disease? Expert review of clinical pharmacology, 2011, Volume: 4, Issue:4 Topics: Animals; Antiparkinson Agents; Humans; Nicotine; Parkinson Disease; Randomized Controlled Trials as Topic; Smoking	2011
α7 nicotinic acetylcholine receptor mediated neuroprotection in Parkinson's disease. Current drug targets, 2012, Volume: 13, Issue:5 Topics: alpha7 Nicotinic Acetylcholine Receptor; Animals; Disease Progression; Dopamine; Humans; Neurons; Neuroprotective Agents; Nicotine; Parkinson Disease; Parkinsonian Disorders; Receptors, Nicotinic; Signal Transduction; Smoking	2012
Nicotine as a potential neuroprotective agent for Parkinson's disease. Movement disorders : official journal of the Movement Disorder Society, 2012, Volume: 27, Issue:8 Topics: Animals; Corpus Striatum; Disease Models, Animal; Humans; Neuroprotective Agents; Nicotine; Nicotinic Agonists; Parkinson Disease; Parkinson Disease, Secondary; Receptors, Nicotinic; Signal Transduction; Smoking; Substantia Nigra	2012
Therapeutic potential of natural products in Parkinson's disease. Recent patents on endocrine, metabolic & immune drug discovery, 2012, Volume: 6, Issue:3 Topics: Animals; Biological Products; Botulinum Toxins; Humans; Levodopa; Neuroprotective Agents; Nicotine; Parkinson Disease; Patents as Topic; Phytic Acid; Phytotherapy; Piper nigrum; Plant Extracts; Zingiber officinale	2012
Nicotine and nicotinic receptors; relevance to Parkinson's disease. Neurotoxicology, 2002, Volume: 23, Issue:4-5 Topics: Animals; Basal Ganglia; Humans; Nerve Degeneration; Neuroprotective Agents; Nicotine; Nicotinic Agonists; Parkinson Disease; Receptors, Nicotinic; RNA, Messenger; Substantia Nigra	2002
[Cigarette smoking and neurological disease]. No to shinkei = Brain and nerve, 2004, Volume: 56, Issue:3 Topics: Alzheimer Disease; Amyotrophic Lateral Sclerosis; Cerebrovascular Circulation; Humans; Intracranial Arteriosclerosis; Multiple Sclerosis; Nicotine; Parkinson Disease; Risk Factors; Smoking; Stroke	2004
Smoking, nicotine and Parkinson's disease. Trends in neurosciences, 2004, Volume: 27, Issue:9 Topics: Animals; Corpus Striatum; Dopamine; Humans; Models, Biological; Neural Pathways; Nicotine; Parkinson Disease; Receptors, Nicotinic; Smoking; Substantia Nigra	2004
Nicotine an efficient tool of the neurobiological research today, the tool of treatment tomorrow? Prague medical report, 2005, Volume: 106, Issue:4 Topics: Animals; Antioxidants; Ganglionic Stimulants; Humans; Nerve Degeneration; Neuroprotective Agents; Nicotine; Nicotinic Agonists; Parkinson Disease; Receptors, Cholinergic; Smoking	2005
Nicotine induces brain CYP enzymes: relevance to Parkinson's disease. Journal of neural transmission. Supplementum, 2006, Issue:70 Topics: Animals; Aryl Hydrocarbon Hydroxylases; Brain; Cytochrome P-450 CYP2B6; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP2E1; Cytochrome P-450 Enzyme System; Enzyme Induction; Humans; Nicotine; Nicotinic Agonists; Oxidoreductases, N-Demethylating; Parkinson Disease	2006
Advances in the treatment of Parkinson's disease. Progress in neurobiology, 2007, Volume: 81, Issue:1 Topics: Animals; Anti-Inflammatory Agents; Antioxidants; Antiparkinson Agents; Brain Tissue Transplantation; Cholinergic Antagonists; Deep Brain Stimulation; Dopamine Agonists; Enzyme Inhibitors; Fetal Tissue Transplantation; Genetic Therapy; Globus Pallidus; Humans; Iron Chelating Agents; Nanotechnology; Neuroprotective Agents; Nicotine; Parkinson Disease; Parkinsonian Disorders; Stem Cell Transplantation; Vaccination; Vitamins	2007
Nicotine neuroprotection against nigrostriatal damage: importance of the animal model. Trends in pharmacological sciences, 2007, Volume: 28, Issue:5 Topics: Animals; Disease Models, Animal; Dopamine; Humans; Mice; Neurons; Neuroprotective Agents; Nicotine; Nicotinic Agonists; Parkinson Disease; Primates; Rats; Substantia Nigra	2007
Nicotinic receptors as CNS targets for Parkinson's disease. Biochemical pharmacology, 2007, Oct-15, Volume: 74, Issue:8 Topics: Animals; Brain; Corpus Striatum; Humans; Neuroprotective Agents; Nicotine; Nicotinic Agonists; Parkinson Disease; Receptors, Nicotinic; Substantia Nigra	2007
Neuroprotection via nAChRs: the role of nAChRs in neurodegenerative disorders such as Alzheimer's and Parkinson's disease. Frontiers in bioscience : a journal and virtual library, 2008, Jan-01, Volume: 13 Topics: Alzheimer Disease; Animals; Binding Sites; Brain; Humans; Models, Biological; Neurodegenerative Diseases; Neuroprotective Agents; Nicotine; Parkinson Disease; Receptors, Nicotinic; Signal Transduction	2008
Genetic and environmental aspects of the role of nicotinic receptors in neurodegenerative disorders: emphasis on Alzheimer's disease and Parkinson's disease. Behavior genetics, 1995, Volume: 25, Issue:2 Topics: Aging; Alzheimer Disease; Animals; Brain Chemistry; Drug Tolerance; Female; Humans; Male; Nerve Degeneration; Nicotine; Parkinson Disease; Receptors, Nicotinic; Sex Factors; Signal Transduction; Up-Regulation	1995
Nicotine as a therapeutic drug. North Carolina medical journal, 1995, Volume: 56, Issue:1 Topics: Alzheimer Disease; Colitis, Ulcerative; Humans; Nicotine; Parkinson Disease	1995
Pharmacology of nicotine and its therapeutic use in smoking cessation and neurodegenerative disorders. Pharmacology & therapeutics, 1996, Volume: 72, Issue:1 Topics: Alzheimer Disease; Animals; Behavior, Animal; Clinical Trials as Topic; Drug Carriers; Humans; Nicotine; Nicotinic Agonists; Parkinson Disease; Receptors, Nicotinic; Smoking Cessation; Substance Withdrawal Syndrome; Substance-Related Disorders	1996
[Nicotine in neuropsychiatric movement disorders]. Fortschritte der Neurologie-Psychiatrie, 1996, Volume: 64, Issue:9 Topics: Adult; Akathisia, Drug-Induced; Brain; Child; Dyskinesia, Drug-Induced; Haloperidol; Humans; Nicotine; Parkinson Disease; Receptors, Dopamine; Tourette Syndrome	1996
Nicotinic system involvement in Alzheimer's and Parkinson's diseases. Implications for therapeutics. Drugs & aging, 1997, Volume: 11, Issue:3 Topics: Alzheimer Disease; Animals; Cognition; Cognition Disorders; Combined Modality Therapy; Disease Models, Animal; Humans; Nicotine; Nicotinic Agonists; Nicotinic Antagonists; Parkinson Disease; Receptors, Nicotinic	1997
Nicotinic acetylcholine receptors in health and disease. Molecular neurobiology, 1997, Volume: 15, Issue:2 Topics: Acetylcholine; Alzheimer Disease; Anesthetics; Animals; Autoimmune Diseases; Cholinergic Agents; Cholinergic Antagonists; Epilepsy; Ethanol; Female; Keratinocytes; Male; Models, Molecular; Muscle Proteins; Myasthenia Gravis; Nerve Tissue Proteins; Neuromuscular Junction; Nicotine; Parkinson Disease; Pregnancy; Protein Conformation; Receptors, Nicotinic; Schizophrenia; Smoking; Torpedo; Tourette Syndrome	1997
Nicotine and brain disorders. Acta pharmacologica Sinica, 2000, Volume: 21, Issue:2 Topics: Alzheimer Disease; Animals; Attention Deficit Disorder with Hyperactivity; Humans; Nicotine; Parkinson Disease; Receptors, Nicotinic; Schizophrenia	2000
Neurotoxicity as a mechanism for neurodegenerative disorders: basic and clinical aspects. Expert opinion on investigational drugs, 2001, Volume: 10, Issue:5 Topics: Alzheimer Disease; Amyotrophic Lateral Sclerosis; Animals; Humans; Levodopa; Nerve Growth Factor; Neuroprotective Agents; Nicotine; Parkinson Disease	2001
Current evidence for neuroprotective effects of nicotine and caffeine against Parkinson's disease. Drugs & aging, 2001, Volume: 18, Issue:11 Topics: Caffeine; Humans; Neuroprotective Agents; Nicotine; Parkinson Disease	2001
Basic and clinical psychopharmacology of nicotine. Clinics in chest medicine, 1991, Volume: 12, Issue:4 Topics: Alzheimer Disease; Animals; Electroencephalography; Evoked Potentials; Humans; Mental Processes; Nicotine; Parkinson Disease; Receptors, Nicotinic	1991
Smoking and Parkinson's disease--a new perspective. Reviews on environmental health, 1991, Volume: 9, Issue:3 Topics: Age Factors; Animals; Diagnosis, Differential; Dopamine; Humans; Mice; Nicotine; Parkinson Disease; Personality; Smoking; Smoking Cessation	1991
Cigarette smoking and Parkinson's disease. Neurology, 1986, Volume: 36, Issue:11 Topics: Brain; Dopamine; Female; Humans; Male; Nicotiana; Nicotine; Parkinson Disease; Plants, Toxic; Smoking	1986
Parkinson's disease perspectives on epidemiology and pathogenesis. Preventive medicine, 1973, Volume: 2, Issue:1 Topics: Adult; Age Factors; Aged; Black People; Brain; Catecholamines; Diagnosis, Differential; Encephalitis Viruses; Female; Herpesviridae; Humans; Male; Middle Aged; Nicotine; Parkinson Disease; Sex Factors; Smoking; Virus Diseases	1973

Trials

11 trial(s) available for nicotine and Idiopathic Parkinson Disease

Article	Year
High-dose transdermal nicotine in Parkinson's disease patients: a randomized, open-label, blinded-endpoint evaluation phase 2 study. European journal of neurology, 2018, Volume: 25, Issue:1 Topics: Aged; Antiparkinson Agents; Drug Therapy, Combination; Endpoint Determination; Female; Humans; Male; Middle Aged; Nicotine; Nicotinic Agonists; Parkinson Disease; Surveys and Questionnaires; Transdermal Patch; Treatment Outcome	2018
Nicotine Gum as a Therapeutic Approach for Low Blood Pressure in Parkinson's Disease: A Randomized Pilot Study. Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco, 2019, 01-04, Volume: 21, Issue:2 Topics: Aged; Chewing Gum; Cross-Over Studies; Double-Blind Method; Female; Heart Rate; Humans; Hypotension; Male; Middle Aged; Nicotine; Parkinson Disease; Pilot Projects; Quality of Life	2019
Dopamine transporter imaging under high-dose transdermal nicotine therapy in Parkinson's disease: an observational study. Nuclear medicine communications, 2009, Volume: 30, Issue:7 Topics: Administration, Cutaneous; Dopamine Plasma Membrane Transport Proteins; Dose-Response Relationship, Drug; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Neostriatum; Nicotine; Parkinson Disease; Regression Analysis; Time Factors; Tomography, Emission-Computed, Single-Photon; Tropanes	2009
Acute nicotine enhances strategy-based semantic processing in Parkinson's disease. The international journal of neuropsychopharmacology, 2011, Volume: 14, Issue:7 Topics: Administration, Cutaneous; Aged; Cognition Disorders; Cross-Over Studies; Factor Analysis, Statistical; Humans; Male; Mental Processes; Middle Aged; Nicotine; Parkinson Disease; Psychomotor Performance; Reaction Time; Semantics	2011
Nicotine effects on general semantic priming in Parkinson's disease. Experimental and clinical psychopharmacology, 2011, Volume: 19, Issue:3 Topics: Age Factors; Aged; Case-Control Studies; Cognition; Cross-Over Studies; Double-Blind Method; Female; Humans; Male; Middle Aged; Nicotine; Nicotinic Agonists; Parkinson Disease; Semantics; Transdermal Patch	2011
Lack of efficacy of a nicotine transdermal treatment on motor and cognitive deficits in Parkinson's disease. Progress in neuro-psychopharmacology & biological psychiatry, 2004, Volume: 28, Issue:1 Topics: Administration, Cutaneous; Aged; Biomechanical Phenomena; Cognition Disorders; Female; Humans; Male; Middle Aged; Movement Disorders; Neuropsychological Tests; Nicotine; Nicotinic Agonists; Parkinson Disease; Psychomotor Performance; Reaction Time; Verbal Learning	2004
Chronic high dose transdermal nicotine in Parkinson's disease: an open trial. European journal of neurology, 2007, Volume: 14, Issue:12 Topics: Administration, Cutaneous; Dopamine Agonists; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Synergism; Humans; Male; Middle Aged; Nausea; Nicotine; Nicotinic Agonists; Parkinson Disease; Pilot Projects; Treatment Outcome	2007
The short-term effect of nicotine chewing gum in patients with Parkinson's disease. Psychopharmacology, 1995, Volume: 117, Issue:2 Topics: Aged; Blood Pressure; Central Nervous System Stimulants; Chewing Gum; Double-Blind Method; Female; Humans; Male; Middle Aged; Nicotine; Parkinson Disease; Polymethacrylic Acids; Polyvinyls; Pulse; Tobacco Use Cessation Devices	1995
Nicotine may relieve symptoms of Parkinson's disease. Psychopharmacology, 1994, Volume: 116, Issue:1 Topics: Administration, Cutaneous; Aged; Chewing Gum; Confusion; Female; Humans; Male; Middle Aged; Muscle Rigidity; Nicotine; Parkinson Disease; Sleep Wake Disorders; Tremor	1994
Worsening of motor performance in patients with Parkinson's disease following transdermal nicotine administration. Movement disorders : official journal of the Movement Disorder Society, 1999, Volume: 14, Issue:6 Topics: Administration, Cutaneous; Adult; Aged; Antiparkinson Agents; Corpus Striatum; Cross-Over Studies; Dopamine; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Motor Skills; Neural Inhibition; Nicotine; Parkinson Disease; Substantia Nigra	1999
Transdermal nicotine in PD: a randomized, double-blind, placebo-controlled study. Neurology, 2001, Sep-25, Volume: 57, Issue:6 Topics: Administration, Cutaneous; Aged; Double-Blind Method; Female; Humans; Male; Middle Aged; Motor Skills; Neurologic Examination; Neuroprotective Agents; Nicotine; Parkinson Disease; Treatment Outcome	2001

Other Studies

72 other study(ies) available for nicotine and Idiopathic Parkinson Disease

Article	Year
Testing efficacy of the nicotine protection of the substantia nigra pars compacta in a rat Parkinson disease model. Ultrastructure study. Ultrastructural pathology, 2022, Jan-02, Volume: 46, Issue:1 Topics: Animals; Dopaminergic Neurons; Male; Nicotine; Parkinson Disease; Pars Compacta; Rats; Rats, Sprague-Dawley; Substantia Nigra	2022
Study of the Effects of Nicotine and Caffeine for the Treatment of Parkinson's Disease. Applied biochemistry and biotechnology, 2023, Volume: 195, Issue:1 Topics: Caffeine; Dopamine; Humans; Mutation; Nicotine; Parkinson Disease; Ubiquitin-Protein Ligases	2023
Nicotine-Mediated Rescue of α-Synuclein Toxicity Requires Synaptic Vesicle Glycoprotein 2 in Drosophila. Movement disorders : official journal of the Movement Disorder Society, 2023, Volume: 38, Issue:2 Topics: alpha-Synuclein; Animals; Dopaminergic Neurons; Drosophila; Glycoproteins; Humans; Nicotine; Parkinson Disease; Synaptic Vesicles	2023
Nicotine-Mediated Recruitment of GABAergic Neurons to a Dopaminergic Phenotype Attenuates Motor Deficits in an Alpha-Synuclein Parkinson's Model. International journal of molecular sciences, 2023, Feb-20, Volume: 24, Issue:4 Topics: alpha-Synuclein; Animals; Dopamine; Dopaminergic Neurons; GABAergic Neurons; Mice; Nicotine; Parkinson Disease; Phenotype; Substantia Nigra	2023
Structural and functional computational analysis of nicotine analogs as potential neuroprotective compounds in Parkinson disease. Computational biology and chemistry, 2020, Volume: 86 Topics: Drug Discovery; Molecular Docking Simulation; Neuroprotective Agents; Nicotine; Parkinson Disease; Receptors, Nicotinic	2020
Dietary nicotine intake and risk of Parkinson disease: a prospective study. The American journal of clinical nutrition, 2020, 10-01, Volume: 112, Issue:4 Topics: Adult; Aged; Diet; Female; Humans; Male; Middle Aged; Nicotine; Parkinson Disease; Proportional Hazards Models; Prospective Studies; Risk; Tobacco Smoke Pollution	2020
Parkinson's: the weirdest disease. Psychological medicine, 2021, Volume: 51, Issue:5 Topics: Animals; Gambling; Humans; Levodopa; Milk; Nicotine; Parkinson Disease; Risk Factors	2021
Nicotine suppresses Parkinson's disease like phenotypes induced by Synphilin-1 overexpression in Drosophila melanogaster by increasing tyrosine hydroxylase and dopamine levels. Scientific reports, 2021, 05-05, Volume: 11, Issue:1 Topics: Animals; Carrier Proteins; Disease Models, Animal; Dopamine; Dopaminergic Neurons; Drosophila melanogaster; Mice; Nerve Tissue Proteins; Nicotine; Nicotinic Agonists; Parkinson Disease; Tyrosine 3-Monooxygenase	2021
Influence of current and previous smoking on current phenotype in Parkinson's disease. Journal of the neurological sciences, 2021, Aug-15, Volume: 427 Topics: Aged; Humans; Middle Aged; Nicotine; Parkinson Disease; Phenotype; Smoking; Smoking Cessation	2021
Patient-driven N-of-1 in Parkinson's Disease. Lessons Learned from a Placebo-controlled Study of the Effect of Nicotine on Dyskinesia. Methods of information in medicine, 2017, Oct-24, Volume: 56, Issue:99 Topics: Dyskinesias; Female; Humans; Levodopa; Middle Aged; Nicotine; Parkinson Disease; Placebos	2017
Induction of cross-tolerance between protective effect of morphine and nicotine in 6-hydroxydopamine-induce neurotoxicity in SH-SY5Y human dopaminergic neuroblastoma cells. The International journal of neuroscience, 2019, Volume: 129, Issue:2 Topics: Apoptosis; Cell Line, Tumor; Cell Survival; DNA Fragmentation; Dopaminergic Neurons; Drug Tolerance; Humans; Morphine; Neuroprotective Agents; Nicotine; Oxidopamine; Parkinson Disease; Parkinsonian Disorders; Reactive Oxygen Species	2019
Nicotine-Induced Neuroprotection in Rotenone In Vivo and In Vitro Models of Parkinson's Disease: Evidences for the Involvement of the Labile Iron Pool Level as the Underlying Mechanism. Neurotoxicity research, 2019, Volume: 35, Issue:1 Topics: Analysis of Variance; Animals; Cell Count; Disease Models, Animal; Dopamine; Dopaminergic Neurons; Dose-Response Relationship, Drug; Embryo, Mammalian; Exploratory Behavior; Fluoresceins; Forelimb; Insecticides; Iron; Male; Medial Forebrain Bundle; Mesencephalon; Motor Activity; Nicotine; Nicotinic Agonists; Parkinson Disease; Pars Compacta; Rats; Rats, Sprague-Dawley; Rotenone; Tubulin; Tyrosine 3-Monooxygenase	2019
Nicotine promotes neuron survival and partially protects from Parkinson's disease by suppressing SIRT6. Acta neuropathologica communications, 2018, 11-08, Volume: 6, Issue:1 Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Aged; Aged, 80 and over; Animals; Animals, Newborn; Apoptosis; Brain; Cell Death; Disease Models, Animal; Exploratory Behavior; Female; Gene Expression Regulation; Humans; Male; Mice; Mice, Transgenic; Neurons; Nicotine; Nicotinic Agonists; Parkinson Disease; Sirtuins	2018
Nicotine protects against manganese and iron-induced toxicity in SH-SY5Y cells: Implication for Parkinson's disease. Neurochemistry international, 2019, Volume: 124 Topics: Cell Line, Tumor; Cell Survival; Cytoprotection; Dose-Response Relationship, Drug; Humans; Iron; Manganese; Nicotine; Parkinson Disease	2019
Nicotine increases lifespan and rescues olfactory and motor deficits in a Drosophila model of Parkinson's disease. Behavioural brain research, 2013, Sep-15, Volume: 253 Topics: Alleles; Animals; Brain; Disease Progression; Drosophila melanogaster; Female; Flight, Animal; Immunohistochemistry; Life Expectancy; Male; Motor Activity; Movement Disorders; Mutation; Nicotine; Nicotinic Agonists; Olfaction Disorders; Parkinson Disease; Sex Characteristics; Smell; Tyrosine 3-Monooxygenase; Ubiquitin-Protein Ligases	2013
Nicotinic receptor agonists reduce L-DOPA-induced dyskinesias in a monkey model of Parkinson's disease. The Journal of pharmacology and experimental therapeutics, 2013, Volume: 347, Issue:1 Topics: Animals; Disease Models, Animal; Dyskinesia, Drug-Induced; Female; Levodopa; Male; Nicotine; Nicotinic Agonists; Parkinson Disease; Receptors, Nicotinic; Saimiri	2013
CHRNB3 c.-57A>G functional promoter change affects Parkinson's disease and smoking. Neurobiology of aging, 2014, Volume: 35, Issue:9 Topics: Aged; Corpus Striatum; Female; Gene Frequency; Genetic Association Studies; Genotype; Heterozygote; Humans; Male; Middle Aged; Nicotine; Octamer Transcription Factor-1; Parkinson Disease; Promoter Regions, Genetic; Receptors, Nicotinic; Smoking	2014
The use of nanopore analysis for discovering drugs which bind to α-synuclein for treatment of Parkinson's disease. European journal of medicinal chemistry, 2014, Dec-17, Volume: 88 Topics: alpha-Synuclein; Binding Sites; Biological Products; Caffeine; Calorimetry; Drug Discovery; Humans; Molecular Conformation; Nanopores; Nicotine; Nuclear Magnetic Resonance, Biomolecular; Parkinson Disease; Protein Folding; Structure-Activity Relationship	2014
Behavior of α-synuclein-drug complexes during nanopore analysis with a superimposed AC field. Electrophoresis, 2017, Volume: 38, Issue:2 Topics: alpha-Synuclein; Caffeine; Electricity; Electrophoresis; Humans; Metformin; Models, Chemical; Nanopores; Nicotine; Parkinson Disease; Pharmaceutical Preparations	2017
Saturation Binding of Nicotine to Synthetic Neuromelanin Demonstrated by Fluorescence Spectroscopy. Neurochemical research, 2016, Volume: 41, Issue:12 Topics: Caffeine; Cysteine; Dopamine; Iron; Melanins; Nicotine; Oxidopamine; Parkinson Disease; Polymerization; Spectrometry, Fluorescence	2016
Nicotine slows down oligomerisation of α-synuclein and ameliorates cytotoxicity in a yeast model of Parkinson's disease. Biochimica et biophysica acta. Molecular basis of disease, 2017, Volume: 1863, Issue:6 Topics: alpha-Synuclein; Humans; Lewy Bodies; Models, Biological; Nicotine; Parkinson Disease; Protein Multimerization; Saccharomyces cerevisiae	2017
Synaptic vesicle glycoprotein 2C (SV2C) modulates dopamine release and is disrupted in Parkinson disease. Proceedings of the National Academy of Sciences of the United States of America, 2017, 03-14, Volume: 114, Issue:11 Topics: Aged; Aged, 80 and over; alpha-Synuclein; Animals; Basal Ganglia; Biomarkers; Disease Models, Animal; Dopamine; Dopaminergic Neurons; Female; Gene Deletion; Gene Expression; Humans; Locomotion; Male; Membrane Glycoproteins; Mice; Mice, Knockout; Mice, Transgenic; Middle Aged; Nerve Tissue Proteins; Nicotine; Parkinson Disease; Protein Binding; Synaptic Vesicles	2017
Continuous and intermittent nicotine treatment reduces L-3,4-dihydroxyphenylalanine (L-DOPA)-induced dyskinesias in a rat model of Parkinson's disease. The Journal of pharmacology and experimental therapeutics, 2008, Volume: 327, Issue:1 Topics: Animals; Corpus Striatum; Disease Models, Animal; Dopamine Plasma Membrane Transport Proteins; Dyskinesia, Drug-Induced; Infusion Pumps; Levodopa; Male; Nicotine; Parkinson Disease; Rats; Rats, Sprague-Dawley	2008
Mechanistic evaluation of alginate-HEC gelisphere compacts for controlled intrastriatal nicotine release in Parkinson's disease. Journal of pharmaceutical sciences, 2009, Volume: 98, Issue:6 Topics: Alginates; Cellulose; Cross-Linking Reagents; Drug Delivery Systems; Elasticity; Gels; Glucuronic Acid; Hexuronic Acids; Humans; Neuroprotective Agents; Nicotine; Parkinson Disease; Phase Transition; Surface Properties; Time Factors; Water	2009
Smoking and Parkinson's disease: does nicotine affect alpha-synuclein fibrillation? Biochimica et biophysica acta, 2009, Volume: 1794, Issue:2 Topics: alpha-Synuclein; Amino Acid Sequence; Anabasine; Benzothiazoles; Chromatography, Gel; Cotinine; Humans; Hydroquinones; Microscopy, Atomic Force; Molecular Sequence Data; Mutation; Nicotine; Parkinson Disease; Protein Binding; Protein Multimerization; Smoking; Thiazoles	2009
Nicotine induces sensitization of turning behavior in 6-hydroxydopamine lesioned rats. Neurotoxicity research, 2009, Volume: 15, Issue:4 Topics: Adrenergic Agents; Analysis of Variance; Animals; Apomorphine; Behavior, Animal; Chromatography, High Pressure Liquid; Corpus Striatum; Disease Models, Animal; Dopamine; Dose-Response Relationship, Drug; Electrochemistry; Functional Laterality; Ganglionic Stimulants; Male; Nicotine; Oxidopamine; Parkinson Disease; Rats; Rats, Wistar; Time Factors	2009
Evaluation of structurally diverse neuronal nicotinic receptor ligands for selectivity at the alpha6( ) subtype. Bioorganic & medicinal chemistry letters, 2009, Aug-01, Volume: 19, Issue:15* Topics: Animals; Chemistry, Pharmaceutical; Dopamine; Drug Design; Humans; Kinetics; Ligands; Mice; Models, Chemical; Nicotine; Parkinson Disease; Protein Binding; Pyrimidines; Receptors, Nicotinic; Smoking Cessation; Structure-Activity Relationship	2009
The expression of CYP2D22, an ortholog of human CYP2D6, in mouse striatum and its modulation in 1-methyl 4-phenyl-1,2,3,6-tetrahydropyridine-induced Parkinson's disease phenotype and nicotine-mediated neuroprotection. Rejuvenation research, 2009, Volume: 12, Issue:3 Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Corpus Striatum; Cytochrome P-450 CYP2D6; Cytochrome P-450 Enzyme System; Cytochrome P450 Family 2; Gene Expression Regulation; Humans; Male; Mice; Neuroprotective Agents; Neurotoxins; Nicotine; Parkinson Disease; Phenotype; Time Factors	2009
Nicotine- and caffeine-mediated changes in gene expression patterns of MPTP-lesioned mouse striatum: Implications in neuroprotection mechanism. Chemico-biological interactions, 2010, Apr-29, Volume: 185, Issue:2 Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Apoptosis; Base Sequence; Caffeine; Disease Models, Animal; Gene Expression Regulation; Injections, Intraperitoneal; Male; Mice; MPTP Poisoning; Neostriatum; Neuroprotective Agents; Neurotoxins; Nicotine; Oligonucleotide Array Sequence Analysis; Oxidative Stress; Parkinson Disease; Receptors, Interleukin-1; Reverse Transcriptase Polymerase Chain Reaction; Time Factors	2010
Decaffeinated coffee and nicotine-free tobacco provide neuroprotection in Drosophila models of Parkinson's disease through an NRF2-dependent mechanism. The Journal of neuroscience : the official journal of the Society for Neuroscience, 2010, Apr-21, Volume: 30, Issue:16 Topics: Animals; Animals, Genetically Modified; Caffeine; Cells, Cultured; Coffee; Disease Models, Animal; Diterpenes; Drosophila; Drosophila Proteins; Female; Humans; Male; Neuroprotective Agents; NF-E2-Related Factor 2; Nicotiana; Nicotine; Parkinson Disease; Plant Extracts	2010
[The protective effect of nicotine on dopaminergic neuron of Parkinson's disease mice]. Zhongguo ying yong sheng li xue za zhi = Zhongguo yingyong shenglixue zazhi = Chinese journal of applied physiology, 2007, Volume: 23, Issue:4 Topics: Animals; Caudate Nucleus; Disease Models, Animal; Dopaminergic Neurons; Female; gamma-Aminobutyric Acid; Male; Mice; Mice, Inbred C57BL; Neuroprotective Agents; Nicotine; Parkinson Disease; Tyrosine 3-Monooxygenase	2007
Protective effects of nicotine against aminochrome-induced toxicity in substantia nigra derived cells: implications for Parkinson's disease. Neurotoxicity research, 2012, Volume: 22, Issue:2 Topics: Animals; Cell Line; Dicumarol; Dopaminergic Neurons; Dose-Response Relationship, Drug; Indolequinones; Mecamylamine; Melanins; Nicotine; Nicotinic Agonists; Nicotinic Antagonists; Parkinson Disease; Rats; Receptors, Nicotinic; Substantia Nigra; Uncoupling Agents	2012
Smoking-induced transient motor deterioration in a levodopa-treated patient with Parkinson's disease. Journal of neurology, 2012, Volume: 259, Issue:11 Topics: Administration, Intranasal; Female; Humans; Levodopa; Middle Aged; Motor Skills Disorders; Nicotine; Parkinson Disease; Smoking	2012
A genetic basis for the variable effect of smoking/nicotine on Parkinson's disease. The pharmacogenomics journal, 2013, Volume: 13, Issue:6 Topics: Animals; Dopamine; Drosophila; Gene Expression; Gene-Environment Interaction; Genome-Wide Association Study; Humans; Models, Biological; Nicotine; Parkinson Disease; Smoking	2013
Is nicotine protective against Parkinson's disease? An experimental analysis. CNS & neurological disorders drug targets, 2012, Nov-01, Volume: 11, Issue:7 Topics: Amphetamine; Animals; Antiparkinson Agents; Apomorphine; Behavior, Animal; Corpus Striatum; Disease Models, Animal; Dopamine; Dopamine Agents; Dopamine D2 Receptor Antagonists; Dopamine Uptake Inhibitors; Interneurons; Male; Nerve Tissue Proteins; Neuroprotective Agents; Nicotine; Oxidopamine; Parkinson Disease; Rats; Rats, Wistar; Receptors, Dopamine D1; Receptors, Dopamine D2; Substantia Nigra	2012
Tobacco, coffee, and Parkinson's disease. BMJ (Clinical research ed.), 2003, Mar-15, Volume: 326, Issue:7389 Topics: Caffeine; Central Nervous System Stimulants; Coffee; Dopamine; Ganglionic Stimulants; Nicotiana; Nicotine; Parkinson Disease; Smoking	2003
Dose-dependent protective effect of coffee, tea, and smoking in Parkinson's disease: a study in ethnic Chinese. Journal of the neurological sciences, 2003, Dec-15, Volume: 216, Issue:1 Topics: Adult; Aged; Aged, 80 and over; Asian People; Caffeine; Case-Control Studies; China; Coffee; Dose-Response Relationship, Drug; Environmental Exposure; Female; Humans; Male; Metals, Heavy; Middle Aged; Neuroprotective Agents; Nicotine; Odds Ratio; Parkinson Disease; Risk Factors; Singapore; Smoking; Statistics as Topic; Tea	2003
[Antagonism of dibenzothiazine derivatives (diparcol, parsidol, phenergan) towards the central effects of nicotine; correspondence with clinical experimentation in Parkinson's disease]. Comptes rendus des seances de la Societe de biologie et de ses filiales, 1950, Volume: 144, Issue:7-8 Topics: Empirical Research; Histamine Antagonists; Nicotine; Parkinson Disease; Parkinsonian Disorders; Phenothiazines; Promethazine	1950
Cigarette smoking in Parkinson's disease: influence on disease progression. Movement disorders : official journal of the Movement Disorder Society, 2004, Volume: 19, Issue:9 Topics: Aged; Aged, 80 and over; Cognition Disorders; Cross-Sectional Studies; Disease Progression; Female; Follow-Up Studies; Humans; Male; Nicotine; Parkinson Disease; Prevalence; Prospective Studies; Severity of Illness Index; Smoking; Substantia Nigra; Surveys and Questionnaires; Tobacco Use Disorder	2004
Partial recovery of striatal nicotinic receptors in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-lesioned monkeys with chronic oral nicotine. The Journal of pharmacology and experimental therapeutics, 2006, Volume: 319, Issue:1 Topics: Animals; Azetidines; Binding Sites; Bridged Bicyclo Compounds, Heterocyclic; Conotoxins; Corpus Striatum; Female; MPTP Poisoning; Nicotine; Parkinson Disease; Pyridines; Receptors, Nicotinic; Saimiri	2006
Neuroprotective effect of nicotine on dopaminergic neurons by anti-inflammatory action. The European journal of neuroscience, 2007, Volume: 26, Issue:1 Topics: Animals; Animals, Newborn; Anti-Inflammatory Agents; Bungarotoxins; Cell Count; Coculture Techniques; Dopamine; Immunohistochemistry; Lipopolysaccharides; Mesencephalon; Microglia; Neurons; Neuroprotective Agents; Nicotine; Nicotinic Antagonists; Nitric Oxide; Parkinson Disease; Rats; Rats, Sprague-Dawley; Reverse Transcriptase Polymerase Chain Reaction; Tumor Necrosis Factor-alpha; Tyrosine 3-Monooxygenase	2007
Combined effects of smoking, coffee, and NSAIDs on Parkinson's disease risk. Movement disorders : official journal of the Movement Disorder Society, 2008, Volume: 23, Issue:1 Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Caffeine; Central Nervous System Stimulants; Coffee; Cognition; Drinking Behavior; Female; Humans; Male; Nicotine; Parkinson Disease; Prevalence; Smoking; Surveys and Questionnaires	2008
Nicotine exposure and Parkinson disease. American journal of epidemiology, 1981, Volume: 114, Issue:2 Topics: Adult; Aged; Female; Humans; Kentucky; Male; Middle Aged; Nicotine; Parkinson Disease; Retrospective Studies; Smoking	1981
Nicotine consumption and Parkinson's disease--does the smoke clear up? Movement disorders : official journal of the Movement Disorder Society, 1995, Volume: 10, Issue:3 Topics: Aged; Animals; Brain; Carrier Proteins; Dopamine Plasma Membrane Transport Proteins; Humans; Liver; Membrane Glycoproteins; Membrane Transport Proteins; Nerve Tissue Proteins; Nicotine; Parkinson Disease; Smoking; Smoking Cessation	1995
Effects of smoking in patients with early-onset Parkinson's disease. Journal of the neurological sciences, 1993, Volume: 117, Issue:1-2 Topics: Adult; Chewing Gum; Corpus Striatum; Dopamine; Female; Humans; Male; Middle Aged; Nicotine; Parkinson Disease; Secretory Rate; Smoking; Stimulation, Chemical	1993
Transient worsening of Parkinson's disease after cigarette smoking. Internal medicine (Tokyo, Japan), 1997, Volume: 36, Issue:9 Topics: Adult; Disease Progression; Humans; Male; Muscle Rigidity; Nicotine; Parkinson Disease; Smoking; Time Factors; Tremor	1997
Effects of nicotine on 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine-induced depression of striatal dopamine content and spontaneous locomotor activity in C57 black mice. Pharmacological research, 1998, Volume: 38, Issue:2 Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Dopamine; Dopamine Agents; Male; Mice; Mice, Inbred C57BL; Motor Activity; Neostriatum; Nicotine; Nicotinic Agonists; Parkinson Disease	1998
Nicotine prevents experimental parkinsonism in rodents and induces striatal increase of neurotrophic factors. Journal of neurochemistry, 1998, Volume: 71, Issue:6 Topics: Animals; Brain-Derived Neurotrophic Factor; Cells, Cultured; Corpus Striatum; Dopamine; Fibroblast Growth Factors; Immunohistochemistry; Male; Mesencephalon; Mice; Mice, Inbred C57BL; Nerve Growth Factors; Neurons; Nicotine; Parkinson Disease; Rats; Rats, Sprague-Dawley; RNA, Messenger; Tyrosine 3-Monooxygenase	1998
Role of excitatory amino acids in the ventral tegmental area for central actions of non-competitive NMDA-receptor antagonists and nicotine. Amino acids, 1998, Volume: 14, Issue:1-3 Topics: 6-Cyano-7-nitroquinoxaline-2,3-dione; alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; Animals; Excitatory Amino Acid Antagonists; Excitatory Amino Acids; Male; Nicotine; Parkinson Disease; Rats; Receptors, N-Methyl-D-Aspartate; Tourette Syndrome; Ventral Tegmental Area	1998
Smoking and Parkinson's disease: a dose-response relationship. Neurology, 1999, Jan-01, Volume: 52, Issue:1 Topics: Aged; Alcohol Drinking; Case-Control Studies; Dose-Response Relationship, Drug; Female; Humans; Male; Michigan; Middle Aged; Nicotine; Nicotinic Agonists; Parkinson Disease; Smoking; Smoking Cessation	1999
Can nicotine help Parkinson's? The Johns Hopkins medical letter health after 50, 1999, Volume: 11, Issue:4 Topics: Humans; Nicotine; Parkinson Disease	1999
In vitro and in vivo studies investigating possible antioxidant actions of nicotine: relevance to Parkinson's and Alzheimer's diseases. Biochimica et biophysica acta, 1999, Jul-07, Volume: 1454, Issue:2 Topics: Alzheimer Disease; Animals; Antioxidants; Brain; Brain Chemistry; Chromatography, Liquid; Cognition; In Vitro Techniques; Iron; Male; Memory; Nicotine; Parkinson Disease; Rats; Rats, Sprague-Dawley; Reactive Oxygen Species; Thiobarbituric Acid Reactive Substances	1999
Nicotine binding in human striatum: elevation in schizophrenia and reductions in dementia with Lewy bodies, Parkinson's disease and Alzheimer's disease and in relation to neuroleptic medication. Neuroscience, 2000, Volume: 98, Issue:1 Topics: Aged; Aged, 80 and over; Alzheimer Disease; Antipsychotic Agents; Cognition Disorders; Female; Humans; Lewy Body Disease; Male; Middle Aged; Neostriatum; Neurodegenerative Diseases; Nicotiana; Nicotine; Parkinson Disease; Plants, Toxic; Radioligand Assay; Receptors, Dopamine D2; Receptors, Nicotinic; Schizophrenia; Sex Factors; Synapses; Tritium	2000
Tryptophan and tyrosine catabolic pattern in neuropsychiatric disorders. Neurology India, 2000, Volume: 48, Issue:3 Topics: Adult; Biogenic Monoamines; Brain Diseases; Brain Neoplasms; Digoxin; Epilepsy, Generalized; Erythrocytes; Fatty Acids, Nonesterified; Female; Glioma; Glycine Agents; Humans; Hydroxymethylglutaryl CoA Reductases; Kynurenic Acid; Magnesium; Male; Microvascular Angina; Middle Aged; Morphine; Narcotics; Nicotine; Nicotinic Agonists; Parkinson Disease; Quinolinic Acid; Schizophrenia; Serum Albumin; Sodium-Potassium-Exchanging ATPase; Strychnine; Tryptophan; Tyrosine; Ubiquinone	2000
Alpha and beta nicotinic acetylcholine receptors subunits and synaptophysin in putamen from Parkinson's disease. Neuropharmacology, 2000, Volume: 39, Issue:13 Topics: Aged; Aged, 80 and over; Amino Acid Sequence; Autoradiography; Blotting, Western; Female; Ganglia, Spinal; Humans; In Vitro Techniques; Male; Molecular Sequence Data; Nicotine; Nicotinic Agonists; Parkinson Disease; Putamen; Receptors, Nicotinic; Synaptophysin	2000
Health news. The sleeper syndrome. Harvard health letter, 2001, Volume: 26, Issue:3 Topics: Alzheimer Disease; Cacao; Humans; Hygiene; Isoxazoles; Margarine; Nicotine; Parkinson Disease; Pyrrolidines; Superoxides	2001
Stimulation of non-alpha7 nicotinic receptors partially protects dopaminergic neurons from 1-methyl-4-phenylpyridinium-induced toxicity in culture. Neuroscience, 2002, Volume: 109, Issue:2 Topics: 1-Methyl-4-phenylpyridinium; alpha7 Nicotinic Acetylcholine Receptor; Animals; Cell Death; Dopamine; Female; Immunohistochemistry; Neurons; Neuroprotective Agents; Nicotine; Organ Culture Techniques; Parkinson Disease; Pregnancy; Rats; Rats, Sprague-Dawley; Receptors, Nicotinic; Substantia Nigra; Tobacco Use Disorder; Tyrosine 3-Monooxygenase	2002
Transdermal nicotine in PD: a randomized, double-blind, placebo-controlled study. Neurology, 2002, Apr-09, Volume: 58, Issue:7 Topics: Administration, Cutaneous; Double-Blind Method; Female; Humans; Male; Nicotine; Nicotinic Agonists; Parkinson Disease; Prospective Studies; Randomized Controlled Trials as Topic; Smoking	2002
Addiction to nicotine is due to high intrinsic levels of dopamine. Medical hypotheses, 1992, Volume: 38, Issue:3 Topics: Dopamine; Humans; Models, Neurological; Nicotine; Parkinson Disease; Risk Factors; Smoking; Tobacco Use Disorder	1992
Comparative alterations of nicotinic and muscarinic binding sites in Alzheimer's and Parkinson's diseases. Journal of neurochemistry, 1992, Volume: 58, Issue:2 Topics: Aged; Alzheimer Disease; Binding Sites; Brain; Choline O-Acetyltransferase; Female; Humans; Male; Muscarine; Nicotine; Parkinson Disease	1992
Relation between nicotine intake and Alzheimer's disease. BMJ (Clinical research ed.), 1991, Jun-22, Volume: 302, Issue:6791 Topics: Adult; Alzheimer Disease; Case-Control Studies; Dementia; Female; Humans; Male; Middle Aged; Nicotine; Parkinson Disease; Smoking	1991
A postmortem study of brain nicotinic receptors in Parkinson's and Alzheimer's disease. Brain research, 1991, Apr-26, Volume: 547, Issue:1 Topics: Aged; Aged, 80 and over; Alzheimer Disease; Brain Chemistry; Cognition Disorders; Humans; Kinetics; Nicotine; Parkinson Disease; Receptors, Nicotinic	1991
Chronic administration of nicotine fails to alter the MPTP-induced neurotoxicity in mice. General pharmacology, 1991, Volume: 22, Issue:4 Topics: Animals; Corpus Striatum; Disease Models, Animal; Dopamine; Male; Mice; Mice, Inbred C57BL; Motor Activity; MPTP Poisoning; Nervous System; Nicotine; Parkinson Disease	1991
Nicotinic receptor abnormalities in Alzheimer's and Parkinson's diseases. Journal of neurology, neurosurgery, and psychiatry, 1987, Volume: 50, Issue:6 Topics: Adult; Age Factors; Aged; Aged, 80 and over; Alzheimer Disease; Dementia; Hippocampus; Humans; Huntington Disease; Middle Aged; Nicotine; Parkinson Disease; Receptors, Nicotinic; Thalamus	1987
Reductions in acetylcholine and nicotine binding in several degenerative diseases. Archives of neurology, 1988, Volume: 45, Issue:7 Topics: Acetylcholine; Aged; Alzheimer Disease; Cerebral Cortex; Choline O-Acetyltransferase; Humans; Nicotine; Parkinson Disease; Receptors, Nicotinic; Supranuclear Palsy, Progressive	1988
Nicotine and tremor. Clinical neuropharmacology, 1988, Volume: 11, Issue:3 Topics: Adult; Aged; Chewing Gum; Female; Humans; Male; Middle Aged; Nicotine; Parkinson Disease; Time Factors; Tremor	1988
Monoamine oxidase B, smoking, and Parkinson's disease. Journal of the neurological sciences, 1986, Volume: 72, Issue:2-3 Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Blood Platelets; Brain; Humans; Hydrazines; Isoenzymes; Mice; Mice, Inbred C57BL; Monoamine Oxidase; Nicotine; Parkinson Disease; Pyridines; Smoking; Thiocyanates	1986
Behavioral and biochemical effects of nicotine in an MPTP-induced mouse model of Parkinson's disease. Pharmacology, biochemistry, and behavior, 1987, Volume: 28, Issue:2 Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Corpus Striatum; Disease Models, Animal; Dopamine; Drug Tolerance; Female; Homovanillic Acid; Mice; Mice, Inbred BALB C; Motor Activity; Nicotine; Olfactory Bulb; Parkinson Disease; Pyridines	1987
Topographic distribution of choline acetyltransferase activity and muscarinic and nicotinic receptors in Parkinson brains. Neurochemical pathology, 1985,Winter, Volume: 3, Issue:4 Topics: Aged; Binding Sites; Brain; Choline O-Acetyltransferase; Humans; Middle Aged; Nicotine; Parkinson Disease; Quinuclidinyl Benzilate; Receptors, Muscarinic; Receptors, Nicotinic	1985
Epidemiologic studies of Parkinson's disease. I. Smoking and Parkinson's disease: a survey and explanatory hypothesis. American journal of epidemiology, 1971, Volume: 94, Issue:1 Topics: Adolescent; Adult; Aged; Amines; Child; Facial Expression; Female; Humans; Male; Middle Aged; Movement Disorders; Nicotine; Parkinson Disease; Parkinson Disease, Secondary; Retrospective Studies; Smoking; Speech Disorders; Time Factors	1971
The antiparkinsonian activity of monoamine oxidase inhibitors and other agents in rats and mice. Archives internationales de pharmacodynamie et de therapie, 1968, Volume: 176, Issue:1 Topics: Animals; Dextroamphetamine; Diphenhydramine; Imipramine; Iproniazid; Isocarboxazid; Mice; Monoamine Oxidase Inhibitors; Nialamide; Nicotine; Nortropanes; Pargyline; Parkinson Disease; Parkinson Disease, Secondary; Perphenazine; Phenelzine; Physostigmine; Rats; Scopolamine; Sulfonic Acids; Tolazoline; Tremor; Tremorine; Trihexyphenidyl; Tryptamines	1968
Effect of adrenaline, noradrenaline, atropine, and nicotine on some types of human tremor. Journal of neurology, neurosurgery, and psychiatry, 1966, Volume: 29, Issue:3 Topics: Adult; Aged; Anxiety; Atropine; Cerebellar Diseases; Epinephrine; Female; Humans; Male; Middle Aged; Nicotine; Norepinephrine; Parkinson Disease; Tremor	1966